DOCSLIB.ORG

Modulation of Histamine H3 Receptors in the Brain of 6-Hydroxydopamine-Lesioned Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modulation of Histamine H3 Receptors in the Brain of 6-Hydroxydopamine-Lesioned Rats European Journal of Neuroscience, Vol.12, pp.3823±3832, 2000 ã Federation of European Neuroscience Societies Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats Oleg V. Anichtchik,1,2 Marko Huotari,3,4 Nina Peitsaro,1 John W. Haycock,5 Pekka T. MaÈnnistoÈ 3 and Pertti Panula1,6 1Department of Biology, AÊ bo Akademi University, BioCity, Artillerigatan 6, 20520, Turku, Finland 2Graduate School of Biomedical Sciences (TuBS), Turku, Finland 3Department of Pharmacology and Toxicology, University of Kuopio, Finland 4Graduate School of Pharmacy, University of Kuopio, Finland 5Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, USA 6Institute of Biomedicine, Department of Anatomy, University of Helsinki, Finland 35 Keywords: GTP-g-[ S] autoradiography, H3 receptor binding, immunohistochemistry, Parkinson's disease Abstract Parkinson's disease is a major neurological disorder that primarily affects the nigral dopaminergic cells. Nigral histamine innervation is altered in human postmortem Parkinson's disease brains. However, it is not known if the altered innervation is a consequence of dopamine de®ciency. The aim of the present study was to investigate possible changes in the H3 receptor system in a well- characterized model of Parkinson's disease ± the 6-hydroxydopamine (6-OHDA) lesioned rats. Histamine immunohistochemistry showed a minor increase of the ®bre density index but we did not ®nd any robust increase of histaminergic innervation in the ipsilateral substantia nigra on the lesioned side. In situ hybridization showed equal histidine decarboxylase mRNA expression on both 3 sides in the posterior hypothalamus. H3 receptors were labelled with N-alpha-[3H]-methyl histamine dihydrochloride ([ H] NAMH). Upregulation of binding to H3 receptors was found in the substantia nigra and ventral aspects of striatum on the ipsilateral side. An 35 increase of GTP-g-[ S] binding after H3 agonist activation was found in the striatum and substantia nigra on the lesioned side. In situ hybridization of H3 receptor mRNA demonstrated region-speci®c mRNA expression and an increase of H3 receptor mRNA in ipsilateral striatum. Thus, the histaminergic system is involved in the pathological process after 6-OHDA lesion of the rat brain at least through H3 receptor. On the later stages of the neurotoxic damage, less H3 receptors became functionally active. Increased H3 receptor mRNA expression and binding may, for example, modulate GABAergic neuronal activity in dopamine-depleted striatum. Introduction Animal models of Parkinson's disease are needed for better et al., 1989). Histamine-containing cell bodies are located exclusively understanding the pathogenesis and for drug screening. in the tuberomammillary nucleus of the posterior hypothalamus, and Neurotoxins, such as 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine their projections extend to all regions of the brain. The involvement (MPTP) or 6-hydroxydopamine (6-OHDA), produce parkinsonism in of the histaminergic system in control of movement has been several species, including ®sh, rodent, primates and humans (Burns suggested, since intracerebroventricular administration of histamine et al., 1983; Langston et al., 1983; Perese et al., 1989; Pollard et al., produces biphasic changes in the locomotor activity (Nistico et al., 1992) and provide useful experimental models. 6-OHDA cannot pass 1980; Tuomisto & Eriksson, 1980), and the histamine-induced through the brain blood barrier, so that intraventicular or intracerebral hypoactivity is inhibited by administration of the histamine H3 injections are needed to produce lesions. 6-OHDA is taken up and receptor antagonist thioperamide (Chiavegatto et al., 1998). accumulates in catecholaminergic nerve terminals, hence the damage Moreover, the central histaminergic system has been suggested to occurs quite speci®cally in these neurotransmitter pathways. The have an inhibitory role in methamphetamine-induced stereotyped cytotoxic effect of 6-OHDA is considered to be related to the behaviour (Ito et al., 1997). formation of oxygen-based free radicals and oxidation products Parkinson's disease is one of the major brain-degenerative (Reader & Dewar, 1999) in catecholaminergic terminals. However, disorders, characterized by bradykinesia, rigidity and resting tremor. during the development of experimental parkinsonism, different other The pathophysiological core of Parkinson's disease is a speci®c neurotransmitter pathways are also modulated, e.g. the serotoniner- degeneration of dopamine-containing nerve cells in the substantia gic, GABAergic and cholinergic ones (Lloyd & Hornykiewicz, 1973; nigra and ventral tegmental area with their projections to striatum, Scatton et al., 1983; Reader & Dewar, 1999). hypothalamus and thalamus. A growing body of evidence indicates The histaminergic cell bodies and ®bres in the rat brain have been possible involvement of the histaminergic system in the pathogenesis mapped with antibodies against histamine (Panula et al., 1984; Panula of Parkinson's disease or animal models of this disease. H3 receptor binding is upregulated in the substantia nigra and striatum of 6-OHDA lesioned rats (Ryu et al., 1994, 1996), but is not changed in the striatum Correspondence: Professor Pertti Panula, as above. of the Parkinson's disease patients (Goodchild et al., 1999). Central E-mail: ppanula@abo.® histamine was unaffected by MPTP treatment in the neocortex and Received 30 March 2000, revised 7 July 2000, accepted 3 August 2000 hypothalamus in mice (Cumming et al., 1989), whereas nigral and 3824 O. V. Anichtchik et al. striatal levels were not examined. Recently we observed increased In order to visualize the histaminergic system in the brain of rats histaminergic innervation in the substantia nigra of Parkinson's bearing unilateral 6-OHDA lesion, we used the immunohistochemical disease patients (Anichtchik et al., 2000). The aim of this study was protocol described previously (Anichtchik et al., 2000) with minor therefore to examine the potential plastic changes of the histaminergic modi®cations. Brie¯y, slides with sections were incubated in the system in rats after 6-OHDA lesion of the medial forebrain bundle antiserum against histamine raised in the rabbit over two nights at lesion with special emphasis on the H3 receptor system. +4 °C. The immunoreactivity was detected using biotin-streptavidin method (Vectastain Elite Kit, Vector Labs, CA, USA). This was Materials and methods ®nished by the coupled oxidation reaction in a solution containing 0.025% diaminobenzidine (Sigma), 0.01% H2O2 and 0.3% NiSO4 in 6-OHDA lesion experiments 0.05 M Tris-HCl buffer, pH 7.6 for 2±3min until a bluish-black Unilateral lesions of the medial forebrain bundle were made in Wistar product of the reaction appeared. Parallel sections were processed for male rats (National Animal Center, University of Kuopio, Finland) antityrosine hydroxylase immunohistochemistry with polyclonal weighing 180±230 g. Thirty minutes before the 6-OHDA infusion the antibodies against tyrosine hydroxylase (2 mg/mL) raised in sheep, rats were injected with desipramine, a noradrenaline uptake blocker af®nity puri®ed and characterized as described (Haycock, 1989). The (20 mg/kg i.p.) to restrict the damage to the dopaminergic system reaction was stopped in distilled water, then slides were dried and only. The animals were anaesthetized with 350 mg/kg chloral hydrate coverslipped with Permount (Fisher Chemical, NJ, USA). Control (i.p.), placed in a Kopf stereotactic frame (David Kopf, Tujunga, sections were incubated as previously described (Panula et al., 1989) USA) and the skull was exposed. A stainless steel guide cannula was with preimmune serum or antiserum HA19C preabsorbed with a lowered through a drilled burr hole 2.0 mm above the target. An histamine±protein conjugate. As an additional control, absence of the infusion needle was lowered 2.0 mm below the lower tip of the guide primary antibody in the ®rst incubation was also used. No cannula. The coordinates measured from bregma for the ®nal infusion immunoreaction was seen in these samples. site in the medial forebrain bundle near substantia nigra were AP 4.4, L 1.2, DV 8.3(Paxinos & Watson, 1986). The volume of freshly H3 binding experiments 3 made infused 6-OHDA (12 mgin4mL of NaCl containing 0.2% H3 receptors were labelled with N-alpha-[methyl- H]-methylhista- ascorbic acid) was 4 mL, given over 8 min using CMA syringes mine dihydrochloride ([3H] NAMH) (NEN Life Science Products, (1 mL) connected to PE 10 type plastic tubing and run by a motor- Inc., MA, USA) (81.500 Ci/mmol). Rats, used for binding experi- driven slow-motion syringe pump (CMA/102, CMA Microdialysis, ments, were decapitated, brains were rapidly removed and fresh Solna, Sweden). The needle was retained in its position for 4 min frozen in a liquid nitrogen. 15 mm thick coronal sections were cut in a after the infusion of 6-OHDA. Following recovery from anaesthesia cryostat at ±20 °C, thaw-mounted on poly (L)-lysine-coated slides and (about 1 week), the animals were housed singly and after the recovery stored at ±70 °C until used. Before binding procedures, slides with period in groups of three to ®ve rats per cage. Water and food were sections were left to thaw and dry at room temperature. The binding available ad libitum. Appropriate permits were obtained for all buffer contained 150 mM Na2/K phosphate buffer pH 7.4, 2 mM 3 studies. Experiments were in accordance with
Load more

Recommended publications
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Accelerated Resensitization of the D 1 Dopamine Receptor-Mediated
    The Journal of Neuroscience, October 1994, 74(10): 6260-6266 Accelerated Resensitization of the D 1 Dopamine Receptor-mediated Response in Cultured Cortical and Striatal Neurons from the Rat: Respective Role of CY1 -Adrenergic and /U-methybaspartate Receptors Fabrice Trovero, Philippe Marin, Jean-PO1 Tassin, JoQl Premont, and Jacques Glowinski INSERM U 114, Chaire de Neuropharmacologie, College de France, 75231 Paris Cedex, France As previously shown in vivo, noradrenergic and glutama- cortex. In the rat, bilateral electrolytic lesions of the mesence- tergic neurons can regulate the denervation supersensitivity phalic ventral tegmental area induce a complex and permanent of Dl dopaminergic (DA) receptors in the rat prefrontal cor- behavioral syndrome characterized by a locomotor hyperactiv- tex and striatum respectively. Therefore, the effects of meth- ity and the incapacity of the animal to focalize its attention (Le oxamine (an al-adrenergic agonist) and glutamate on the Moal et al., 1969). Some of the behavioral deficits observed in resensitization of Dl DA receptors were investigated in cul- the lesioned animals, particularly the locomotor hyperactivity, tured cortical and striatal neurons from the embryonic rat. have been attributed for a large part to the selective destruction In the presence of sulpiride and propranolol, DA stimulated of the cortical dopaminergic (DA) innervation (Tassin et al., the Dl DA receptor-mediated conversion of 3H-adenine into 1978). This locomotor hyperactivity was markedly reduced in 3H-cAMP in both intact cortical and striatal cells and these rats with 6-hydroxydopamine (6-OHDA) lesions,which destroy responses were markedly desensitized in cells preexposed not only the ascendingDA neurons but also the ascendingnor- for 15 min to DA (50 AM).
    [Show full text]
  • TAAR1 Modulates Cortical Glutamate NMDA Receptor Function
    Neuropsychopharmacology (2015) 40, 2217–2227 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org TAAR1 Modulates Cortical Glutamate NMDA Receptor Function Stefano Espinoza1, Gabriele Lignani1, Lucia Caffino2, Silvia Maggi1, Ilya Sukhanov1,3, Damiana Leo1, Liudmila Mus1, Marco Emanuele1, Giuseppe Ronzitti1, Anja Harmeier4, Lucian Medrihan1, 1,5 1 4 1 1 Tatyana D Sotnikova , Evelina Chieregatti , Marius C Hoener , Fabio Benfenati , Valter Tucci , 2 *,1,5,6 Fabio Fumagalli and Raul R Gainetdinov 1Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genova, Italy; 2Dipartimento di Scienze Farmacologiche e 3 Biomolecolari, Università degli Studi di Milano, Milan, Italy; Department of Pharmacology, St Petersburg State Medical University, Petersburg, 4 Russia; Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Area, pRED, Roche Innovation Center Basel, F. Hoffmann- 5 La Roche Ltd, Basel, Switzerland; Institute of Translational Biomedicine, Faculty of Biology, St Petersburg State University, St Petersburg, Russia; 6 Skolkovo Institute of Science and Technology (Skoltech) Skolkovo, Moscow region, Russia Trace Amine-Associated Receptor 1 (TAAR1) is a G protein-coupled receptor expressed in the mammalian brain and known to influence subcortical monoaminergic transmission. Monoamines, such as dopamine, also play an important role within the prefrontal cortex (PFC) circuitry, which is critically involved in high-o5rder cognitive processes. TAAR1-selective ligands have shown potential antipsychotic, antidepressant, and pro-cognitive effects in experimental animal models; however, it remains unclear whether TAAR1 can affect PFC- related processes and functions. In this study, we document a distinct pattern of expression of TAAR1 in the PFC, as well as altered subunit composition and deficient functionality of the glutamate N-methyl-D-aspartate (NMDA) receptors in the pyramidal neurons of layer V of PFC in mice lacking TAAR1.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • Evolution of Dopamine Receptor Genes of the D1 Class in Vertebrates
    Evolution of Dopamine Receptor Genes of the D1 Class in Vertebrates Kei Yamamoto,1 Olivier Mirabeau,1 Charlotte Bureau,1 Maryline Blin,1 Sophie Michon-Coudouel,z,1 Michae¨l Demarque,1 and Philippe Vernier*,1 1Neurobiology & Development (UPR 3294), Institute of Neurobiology Alfred Fessard, CNRS Gif-sur-Yvette, France zPresent address: Universite´ de Rennes 1, Observatoire des Sciences de l’Univers, Rennes, France *Corresponding author: E-mail: [email protected]. Associate editor: Joel Dudley Abstract The receptors of the dopamine neurotransmitter belong to two unrelated classes named D1 and D2.FortheD1 receptor class, only two subtypes are found in mammals, the D1A and D1B, receptors, whereas additional subtypes, named D1C,D1D, and D1X, have been found in other vertebrate species. Here, we analyzed molecular phylogeny, gene synteny, and gene expression pattern of the D1 receptor subtypes in a large range of vertebrate species, which leads us to propose a new view of the evolution of D1 dopamine receptor genes. First, we show that D1C and D1D receptor sequences are encoded by orthologous genes. Second, the previously identified Cypriniform D1X sequence is a teleost-specific paralog of the D1B sequences found in all groups of jawed vertebrates. Third, zebrafish and several sauropsid species possess an additional D1-like gene, which is likely to form another orthology group of vertebrate ancestral genes, which we propose to name D1E. Ancestral jawed vertebrates are thus likely to have possessed four classes of D1 receptor genes—D1A, D1B(X), D1C(D), and D1E—which arose from large-scale gene duplications. The D1C receptor gene would have been secondarily lost in the mammalian lineage, whereas the D1E receptor gene would have been lost independently in several lineages of modern vertebrates.
    [Show full text]
  • Pharmacological Manipulation of D1-Dopamine Receptor Function in Schizophrenia Göran C
    Pharmacological Manipulation of D1-Dopamine Receptor Function in Schizophrenia Göran C. Sedvall, M.D., Ph.D., and Per Karlsson, M.D. The most widely accepted hypothesis concerning the trial of SCH 39166, a selective D1-dopamine receptor pathophysiology of schizophrenia, the dopamine hypothesis, antagonist, showed no evidence of antipsychotic activity in suggests that the symptoms of schizophrenia are mediated schizophrenic patients. Instead, it appeared that selective in part by a functional hyperactivity in the dopamine D1-receptor antagonism may have aggravated symptoms. system in the brain, primarily at D2-dopamine receptors. Although these findings do not support the prediction that Recent data suggest that D1-dopamine receptors may also selective D1-dopamine receptor antagonism produces play a major role in the pathophysiology of schizophrenia. antipsychotic effects, they do not preclude the possibility Using positron emission tomography (PET), increased that combined D1- and D2-receptor antagonism may act variability and reduced D1-receptor binding have been synergistically to ameliorate symptoms in schizophrenia. In observed in the basal ganglia and frontal cortex of drug- addition, clinical evaluation of D1 agonists in schizophrenia naive schizophrenia patients. Such alterations have also should be undertaken. [Neuropsychopharmacology been found in some in vitro studies. These results suggest 22:S181–S188, 1999] © 1999 American College of that the ratio of D1- over D2-regulated dopamine signaling Neuropsychopharmacology. Published by Elsevier in some brain regions is reduced in schizophrenia. A clinical Science Inc. KEY WORDS: Schizophrenia; Dopamine; D1 receptor; D2 tral dopamine receptor subtypes (D1, D2, D3, D4, and D5) receptor; Positron emission tomography (PET); (Sunahara et al.
    [Show full text]
  • The Histamine H3 Receptor: Structure, Pharmacology and Function
    Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104752 The histamine H3 receptor: structure, pharmacology and function Gustavo Nieto-Alamilla, Ricardo Márquez-Gómez, Ana-Maricela García-Gálvez, Guadalupe-Elide Morales-Figueroa and José-Antonio Arias-Montaño Downloaded from Departamento de Fisiología, Biofísica y Neurociencias, molpharm.aspetjournals.org Centro de Investigación y de Estudios Avanzados (Cinvestav-IPN), Av. IPN 2508, Zacatenco, 07360 México, D.F., México at ASPET Journals on September 29, 2021 Running title: The histamine H3 receptor Correspondence to: Dr. José-Antonio Arias-Montaño Departamento de Fisiología, Biofísica y Neurociencias Cinvestav-IPN Av. IPN 2508, Zacatenco 07360 México, D.F., México. Tel. (+5255) 5747 3964 Fax. (+5255) 5747 3754 Email [email protected] 1 Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ from this version. MOL #104752 Text pages 66 Number of tables 3 Figures 7 References 256 Words in abstract 168 Downloaded from Words in introduction 141 Words in main text 9494 molpharm.aspetjournals.org at ASPET Journals on September 29, 2021 2 Molecular Pharmacology Fast Forward. Published on August 25, 2016 as DOI: 10.1124/mol.116.104752 This article has not been copyedited and formatted. The final version may differ
    [Show full text]
  • Regulation of Natural Killer Cell Activity by Glucocorticoids, Serotonin, Dopamine, and Epinephrine
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE OPEN Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine Silvia Capellino1, Maren Claus1 and Carsten Watzl 1 The immune system and the nervous system are highly complex organs composed of various different cells that must interact with each other for proper function of the system. This communication can be mediated by soluble factors. The factors released by the nervous system (neurotransmitters) differ from those released by the immune system (cytokines). Nevertheless, the nervous and immune systems can influence each other’s activity because immune cells express neurotransmitter receptors, and neurons express cytokine receptors. Moreover, immune cells can synthesize and release neurotransmitters themselves, thus using neurotransmitter- mediated pathways via autocrine and paracrine mechanisms. Natural killer (NK) cells are innate lymphocytes that are important for early and effective immune reactions against infections and cancer. Many studies have shown the strong influence of stress and the nervous system on NK cell activity. This phenomenon may be one reason why chronic stress leads to a higher incidence of infections and cancer. Here, we review the effects of neuroendocrine factors on the different activities of NK cells. Understanding the effects of neuroendocrine factors on NK cell activities during physiological and pathophysiological conditions may result in novel therapeutic strategies to enhance NK cell functions against tumors. Keywords: Natural Killer Cells; Catecholamines; Glucocorticoids; Neurotransmitters 1234567890();,: Cellular & Molecular Immunology (2020) 17:705–711; https://doi.org/10.1038/s41423-020-0477-9 INTRODUCTION experienced, and body movements are coordinated. The periph- Both the immune system and the nervous system are highly eral nervous system consists of all neurons that exist outside of complex organs that have some interesting similarities.
    [Show full text]
  • Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists As New Therapeutic Agents Adeline Etievant#, Cécile Bétry#, and Nasser Haddjeri*,1
    The Open Neuropsychopharmacology Journal, 2010, 3, 1-12 1 Open Access Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents Adeline Etievant#, Cécile Bétry#, and Nasser Haddjeri*,1 Laboratory of Neuropharmacology, Faculty of Pharmacy, University Lyon I, EAC CNRS 5006, 8 Avenue Rockefeller 69373 LYON Cedex 08 France Abstract: The therapeutic efficacy of current antipsychotic or antidepressant agents still present important drawbacks such as delayed onset of action and a high percentage of non-responders. Despite significant advancements in the devel- opment of new drugs with more acceptable side-effect profiles, patients with schizophrenia or major depression experi- ence substantial disability and burden of disease. The present review discusses the usefulness of partial dopamine D2/serotonin 5-HT1A receptors agonists in the treatment of schizophrenia, major depression and bipolar disorder as well as in Parkinson’s disease. Partial agonists can behave as modulators since their intrinsic activity or efficacy of a partial ago- nist depends on the target receptor population and the local concentrations of the natural neurotransmitter. Thus, these drugs may restore adequate neurotransmission while inducing less side effects. In schizophrenia, partial DA D2/5-HT1A receptor agonists (like aripiprazole or bifeprunox), by stabilizing DA system via a preferential reduction of phasic DA re- lease, reduce side effects i.e. extrapyramidal symptoms and improve cognition by acting on 5-HT1A receptors. Aripipra- zole appears also as a promising agent for the treatment of depression since it potentiates the effect of SSRIs in resistant treatment depression. Concerning bipolar disorders aripiprazole may have only a benefit effect in the treatment of manic episodes.
    [Show full text]
  • 5-HT2A Receptors in the Central Nervous System the Receptors
    The Receptors Bruno P. Guiard Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System The Receptors Volume 32 Series Editor Giuseppe Di Giovanni Department of Physiology & Biochemistry Faculty of Medicine and Surgery University of Malta Msida, Malta The Receptors book Series, founded in the 1980’s, is a broad-based and well- respected series on all aspects of receptor neurophysiology. The series presents published volumes that comprehensively review neural receptors for a specific hormone or neurotransmitter by invited leading specialists. Particular attention is paid to in-depth studies of receptors’ role in health and neuropathological processes. Recent volumes in the series cover chemical, physical, modeling, biological, pharmacological, anatomical aspects and drug discovery regarding different receptors. All books in this series have, with a rigorous editing, a strong reference value and provide essential up-to-date resources for neuroscience researchers, lecturers, students and pharmaceutical research. More information about this series at http://www.springer.com/series/7668 Bruno P. Guiard • Giuseppe Di Giovanni Editors 5-HT2A Receptors in the Central Nervous System Editors Bruno P. Guiard Giuseppe Di Giovanni Faculté de Pharmacie Department of Physiology Université Paris Sud and Biochemistry Université Paris-Saclay University of Malta Chatenay-Malabry, France Msida MSD, Malta Centre de Recherches sur la Cognition Animale (CRCA) Centre de Biologie Intégrative (CBI) Université de Toulouse; CNRS, UPS Toulouse, France The Receptors ISBN 978-3-319-70472-2 ISBN 978-3-319-70474-6 (eBook) https://doi.org/10.1007/978-3-319-70474-6 Library of Congress Control Number: 2017964095 © Springer International Publishing AG 2018 This work is subject to copyright.
    [Show full text]
  • Establishing Stable Cell Lines
    Establishing Stable Cell Lines 1. Our proprietary expression system for mammalian cells is used. 2. Our stable cell lines are from the single colonies, not from the pool. 3. Many single clones are screened, and three best ones are kept. 4. Functional assay is performed to confirm the clones’ biological function. 5. Time frame: 2 – 3 months for one stable cell line List of In-Stock ACTOne GPCR Stable Clones Transduced Gi-coupled receptors (22) Transduced Gs coupled receptors (34) Cannabinoid receptor 1 (CB1) Vasoactive Intestinal Peptide Receptor 2 (VIPR2) Dopamine Receptor 2 (DRD2) Melanocortin 4 Receptor (MC4R) Melanocortin 5 Receptor (MC5R) Somatostatin Receptor 5 (SSTR5) Parathyroid Hormone Receptor 1 (PTHR1) Adenosine A1 Receptor (ADORA1) Glucagon Receptor (GCGR) Chemokine (C-C motif) receptor 5 (CCR5) Dopamine Receptor 1 (DRD1) Melanin-concentrating Hormone Receptor 1 (MCHR1) Prostaglandin E Receptor 4 (EP4) Vasoactive Intestinal Peptide Receptor 1 (VIPR1) Cannabinoid receptor 2 (CB2) Gastric Inhibitor Peptide Receptor (GIPR) Glutamate receptor, metabotropic 8 (GRM8) Dopamine Receptor 5 (DRD5) Opioid receptor, kappa 1 (OPRK1) Parathyroid Hormone Receptor 2 (PTHR2) Adenosine A3 receptor (ADORA3) 5-hydroxytryptamine (serotonin) receptor 6 (HTR4) Corticotropin Releasing Hormone Receptor 2 (CRHR2) Glutamate receptor, metabotropic 8 (GRM8) Adenylate Cyclase Activating Polypeptide 1 Receptor type I (ADCYAP1R1) Neuropeptide Y Receptor Y1 (NPY1R) Secretin Receptor (SCTR) Neuropeptide Y Receptor Y2 (NPY2R) Follicle
    [Show full text]
  • Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat
    The Journal of Neuroscience, August 15, 2002, 22(16):7272–7280 Ciproxifan, a Histamine H3-Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat Catherine Pillot,1 Jordi Ortiz,1 Anne He´ ron,1 Sophie Ridray,1 Jean-Charles Schwartz,2 and Jean-Michel Arrang2 1Laboratoire de Physiologie, Faculte´ des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France, and 2Unite´de Neurobiologie et Pharmacologie Mole´ culaire de l’Institut National de la Sante´ et de la Recherche Me´ dicale, Centre Paul Broca, 75014 Paris, France By using double in situ hybridization performed with proen- Similarly, whereas it was devoid of any motor effect when kephalin and H3-receptor riboprobes on the same sections used alone, ciproxifan strongly potentiated haloperidol-induced from rat brain, we show that histamine H3 receptors are ex- locomotor hypoactivity and catalepsy, two behaviors in which pressed within striatopallidal neurons of the indirect movement striatal neurons are involved. The strong H3-receptor mRNA pathway. The majority (ϳ70%) of striatal enkephalin neurons expression in enkephalin neurons suggests that the synergistic express H3-receptor mRNAs. neurochemical and motor effects of ciproxifan and haloperidol This important degree of coexpression of proenkephalin and result from direct H3 /D2-receptor interactions, leading to an H3-receptor mRNAs prompted us to explore the effect of H3- enhanced activation of striatopallidal neurons of the indirect receptor ligands on the regulation of enkephalin mRNA expression movement pathway. The potentiation of the effects of haloper- in the striatum. Acute administration of ciproxifan, a H -receptor 3 idol by ciproxifan strengthens the potential interest of H - antagonist/inverse agonist, did not modify the expression of the 3 receptor antagonists/inverse agonists to improve the symptom- neuropeptide by itself but strongly increased the upregulation of atic treatment of schizophrenia.
    [Show full text]